A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,360

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Interventions

DRUG

JMT103

120 mg by subcutaneous injection every 4 weeks

DRUG

zoledronic acid

4 mg by intravenous drip (100mL:4mg) every 4 weeks

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY